Processa Pharmaceuticals (PCSA) Long-Term Debt Issuances (2012 - 2018)
Processa Pharmaceuticals' (PCSA) quarterly Long-Term Debt Issuances came in at -$9484.0 in Q3 2018, down 100.42% on a QoQ basis from $2.3 million in Q4 2017.
Processa Pharmaceuticals (PCSA) Long-Term Debt Issuances (2012 - 2018) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 7 years of Long-Term Debt Issuances data on file, last reported at -$9484.0 in Q3 2018.
- Quarterly Long-Term Debt Issuances changed N/A year-over-year to -$9484.0 in Q3 2018, while the trailing twelve-month figure through Dec 2020 was $2.2 million (changed N/A YoY) and the FY2020 annual result came in at $162459.0, down 79.82% from the prior year.
- Long-Term Debt Issuances retreated to -$9484.0 in Q3 2018, from $2.3 million in the prior quarter.
- In the past five years, Long-Term Debt Issuances ranged from a high of $2.3 million in Q4 2017 to a low of -$1.5 million in Q3 2014.
- A 5-year average of $211267.8 and a median of $13861.0 in 2014 frame the typical range for Long-Term Debt Issuances.
- Annual changes were most pronounced in 2014 — Long-Term Debt Issuances tumbled 15618.34% — and 2015, when it jumped 4203.34%.
- Tracing PCSA's Long-Term Debt Issuances over 5 years: stood at $13861.0 in 2014, then tumbled by 5388.93% to -$733098.0 in 2015, then surged by 102.05% to $15000.0 in 2016, then soared by 14920.0% to $2.3 million in 2017, then tumbled by 100.42% to -$9484.0 in 2018.
- The last three Long-Term Debt Issuances figures came in at -$9484.0 (Q3 2018), $2.3 million (Q4 2017), and $15000.0 (Q1 2016), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Processa Pharmaceuticals | 5.69 Mn | 5.69 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | -9,484.00 |
| Sep 30, 2018 | -9,484.00 |
| Dec 31, 2017 | 2.25 Mn |
| Dec 31, 2017 | 2.25 Mn |
| Mar 31, 2016 | 15,000.00 |
| Mar 31, 2016 | 15,000.00 |
| Dec 31, 2015 | -733,098.00 |
| Dec 31, 2015 | -733,098.00 |
| Sep 30, 2015 | 724,968.00 |
| Sep 30, 2015 | 724,968.00 |
| Jun 30, 2015 | -421,968.00 |
| Jun 30, 2015 | -421,968.00 |
| Mar 31, 2015 | 450,000.00 |
| Mar 31, 2015 | 450,000.00 |
| Dec 31, 2014 | 13,861.00 |
| Dec 31, 2014 | 13,861.00 |
| Sep 30, 2014 | -1.54 Mn |
| Sep 30, 2014 | -1.54 Mn |
| Jun 30, 2014 | 1.56 Mn |
| Jun 30, 2014 | 1.56 Mn |